William J. Gradishar, MD | Authors


Updates to NCCN Guidelines on Molecular Assays for Patients With Breast Cancer

April 08, 2019

William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.

Takeaways From TransATAC Trial on Comparing Prognostic Signatures

December 10, 2016

William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.